Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Naphazoline
Drug ID BADD_D01531
Description Naphazoline is a rapid acting imidazoline sympathomimetic vasoconstrictor of ocular or nasal artierioles[L5804,L5807]. It acts to decrease congestion and is found in many over the counter (OTC) eye drops and nasal preparations[L5804,L5807]. Naphazoline was first developed in 1942 as a nasal formulation for congestion[A176609].
Indications and Usage Naphazoline is indicated for use as OTC eyedrops for ocular vasoconstriction or as a nasal preparation for nasal congestion[A176558,L5804,L5807].
Marketing Status approved; investigational
ATC Code R01AA08; R01AB02; S01GA01
DrugBank ID DB06711
KEGG ID D08253
MeSH ID D009278
PubChem ID 4436
TTD Drug ID D0O6IZ
NDC Product Code Not Available
UNII H231GF11BV
Synonyms Naphazoline | AK-Con | AK Con | Albalon | All Clear | Clear Eyes | Colirio Alfa | Idril | Miraclar | Nafazair | Naphazoline Hydrochloride | Hydrochloride, Naphazoline | Naphazoline Monohydrochloride | Monohydrochloride, Naphazoline | Naphazoline Nitrate | Nitrate, Naphazoline | Naphcon | Naphcon Forte | Optazine | Privine | Privin | Proculin | Siozwo | Tele-Stulln | Tele Stulln | Vasoclear | Vasocon | Vasocon Regular | Vasoconstrictor Pensa | Pensa, Vasoconstrictor | VasoNit | Afazol Grin
Chemical Information
Molecular Formula C14H14N2
CAS Registry Number 835-31-4
SMILES C1CN=C(N1)CC2=CC=CC3=CC=CC=C32
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Asthenia08.01.01.001--Not Available
Discomfort08.01.08.003--Not Available
Dizziness02.11.04.006; 24.06.02.007; 17.02.05.003--
Endophthalmitis11.01.06.003; 06.04.05.009--
Erythema23.03.06.001--Not Available
Eye disorder06.08.03.001--Not Available
Eye pain06.08.03.002--
Headache17.14.01.001--
Hyperglycaemia14.06.02.002; 05.06.02.002--
Hyperhidrosis23.02.03.004; 08.01.03.028--
Hypertension24.08.02.001--
Intraocular pressure increased13.07.04.002--Not Available
Keratitis06.04.02.002--
Lacrimation increased06.08.02.004--
Mydriasis17.02.11.003; 06.05.03.004--Not Available
Nausea07.01.07.001--
Nervousness19.06.02.003--Not Available
Ocular hyperaemia06.04.05.004--Not Available
Punctate keratitis06.04.02.003--Not Available
Somnolence19.02.05.003; 17.02.04.006--
Tension19.06.02.005--Not Available
Vision blurred17.17.01.010; 06.02.06.007--
Xerosis08.01.03.016--Not Available
Eye oedema06.08.03.013--Not Available
Ocular discomfort06.08.03.008--Not Available
Accidental exposure to product12.09.01.001--Not Available
The 1th Page    1    Total 1 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene